Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.